0 Blood test could detect kidney cancer up to 5 years earlier
A marker, termed KIM-1, in the blood could be utilized to predict the risk of developing renal cell carcinoma.
Browsing: Disease Area > Endocrine
0 Exploring the Thyroid Imaging Reporting and Data System (TI-RADS): an interview with Franklin Tessler
Find out more about Ti-Rads, guidelines for an ultrasound-based risk stratification system to identify nodules that merit biopsy or sonographic follow-up.
0 FDA approves first-in-class treatment for rare adrenal tumors
The US FDA has approved Progenics Pharmaceuticals’ Adzera®, a first-in-class treatment for two rare adrenal tumors: pheochromocytoma and paraganglioma.
0 Sodium thiosulphate halves hearing loss in children following cancer treatment
A novel drug shows promise for preventing hearing loss in children after chemotherapy treatment for liver cancer.
0 ASCO18: Is surgery necessary for advanced kidney cancer?
A Phase III trial presented at ASCO has suggested that surgery might not be a necessity for patients suffering from advanced kidney cancer.
0 Nivolumab + ipilimumab combo approved as first-line treatment for advanced renal cell carcinoma
The FDA has approved the first immuno-oncology combination therapy for patients with advanced renal cell carcinoma.
0 Born to be bad: researchers identify the genetic roots of ‘killer’ kidney cancers
In a landmark genetics study, a multi-institutional group of researchers have uncovered three distinct evolutionary paths for kidney cancer, allowing them to determine whether a tumor will be aggressive.
0 Cyramza® meets primary endpoint of overall survival in liver cancer study
Eli Lilly have announced that Cyramza® has met its primary endpoint of overall survival, as well as its secondary goal of progression-free survival in late-stage liver cancer study.
0 Advancing treatment options for medullary thyroid cancer: an interview with Jonathan Wadsley
To mark Rare Disease Day we recently spoke with Jonathan Wadsley (Weston Park Hospital, Sheffield, UK) about recent advancements in care for medullary thyroid cancer.
0 Endogenous virus expression could help predict RCC responsiveness to immune checkpoint therapy
Recently at the 2018 ASCO-SIC Clinical immune-oncology symposium (CA, USA, 25-27 January) a panel discussed the science presented in a…
